DUBLIN–(BUSINESS WIRE)–The “Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market by Product (Instruments, Reagents & Consumables, Software & Services), Application (Clinical, Research, Forensic), End-user (Hospitals & Diagnostic Centers, Pharma Biotech, CROs), and Region – Forecast to 2025” report has been added to ResearchAndMarkets.com’s offering.
The global dPCR and qPCR market is projected to reach USD 7.6 billion by 2025 from USD 4.9 billion in 2020, at a CAGR of 9%.
The growth of this market is driven majorly by factors such as the rising incidence of target infectious diseases and genetic disorders; technological advancements in PCR technologies; increasing investments, funds, and grants; increasing use of biomarker profiling for disease diagnostics; and successful completion of the Human Genome Project. On the other hand, high instrument costs – especially that of dPCR – and the technical limitations of PCR are restraining market growth.
By application, the clinical applications segment (of qPCR) is expected to grow at the highest CAGR during the forecast period
Based on application, the qPCR market is segmented into clinical applications, research applications, and forensic applications. The clinical applications segment is expected to register the highest growth during the forecast period. The key factors driving the market growth include the growing usage of qPCR in disease diagnosis, rising incidence of infectious & genetic diseases, and growing public emphasis on early & effective disease diagnosis & treatment.
By end-user, the hospitals and diagnostics centers segment dominated the dPCR market in 2019
Based on end-user, the dPCR market is segmented into Hospitals and Diagnostic Centers, Research Laboratories and Academic Institutes, Pharmaceutical and Biotechnology Companies, Clinical Research Organizations, and Forensic Laboratories. The Hospitals and Diagnostic Centers segment accounted for the largest share of the dPCR market in 2019, primarily due to the growing demand for early and efficient disease diagnosis and treatment, increasing number of dPCR product launches for diagnostic applications, benefits offered by dPCR in disease diagnosis (as compared to other PCR technologies), and growing public awareness related to the benefits offered by dPCR in disease diagnosis.
Asia-Pacific dPCR and qPCR market is expected to witness the highest growth during the forecast period
The Asia-Pacific market is estimated to grow at the highest CAGR during the forecast period, primarily due to the ongoing expansion & modernization of the healthcare infrastructure in emerging Asian countries; increasing number of research projects in China, India, and Japan in the field of genomics and cancer; the rising trend of clinical research being outsourced to Asia-based CROs by leading drug manufacturing companies; and continuous government support for genomics-based research activities in emerging Asia-Pacific countries.
Market Dynamics
Drivers
- Rising Incidence of Target Infectious Diseases and Genetic Disorders
- Technological Advancements in PCR Technologies
- Increasing Investments, Funds, and Grants
- Increasing Use of Biomarker Profiling for Disease Diagnostics
- Successful Completion of the Human Genome Project
Restraints
- High Device Costs Associated with dPCR
- Technical Limitations of qPCR and dPCR Techniques
Opportunities
- Growing Market Penetration in Emerging Countries
- Shift from Plant-Derived to Genome-based Drug Discovery
Challenges
- Adoption and Implementation of MIQE Guidelines
Trends
- Development of Compact, Portable, and Lab-On-Chip PCR Devices
- Ongoing Technological Integration with the PCR Process
Companies Mentioned
- Abbott Laboratories
- Agilent Technologies
- Analytik Jena AG
- Becton, Dickinson and Company
- Bio Molecular Systems
- Bio-Rad Laboratories
- Biomeme
- bioMerieux S.A.
- Bioneer Corporation
- Cole-Parmer Instrument Company
- Danaher Corporation
- Elitech Group
- Enzo Life Sciences
- Eppendorf AG
- Fluidigm Corporation
- Genome Diagnostics Pvt. Ltd.
- JN Medsys Pte. Ltd.
- Kyratec
- LGC Biosearch Technologies
- Merck KGaA
- Meridian Bioscience
- Promega Corporation
- Qiagen N.V.
- Quanta Biosciences
- Quidel Corporation
- Roche Diagnostics
- Sacace Biotechnologies S.R.L.
- Stilla Technologies
- Takara Bio
- Thermo Fisher Scientific
For more information about this report visit https://www.researchandmarkets.com/r/4×1816
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900